TY  - JOUR

T1  - Abstract 3413: Dissecting the combination of gemcitabine and the Chk1 inhibitor MK-8776 <i>in vitro</i> and <i>in vivo</i>: cell cycle perturbation and the impact of administration schedule.

JO  - Cancer Research

UR  - http://dx.doi.org/10.1158/1538-7445.am2013-3413

PY  - 2013/04/15

AU  - Eastman A

AU  - Montano R

AU  - Thompson R

AU  - Khan N

AU  - Hou H

AU  - Lewis LD

AU  - Seigne JD

AU  - Ernstoff MS

ED  - 

DO  - DOI: 10.1158/1538-7445.am2013-3413

PB  - American Association for Cancer Research (AACR)

VL  - 73

IS  - 8_Supplement

SP  - 3413

EP  - 3413

Y2  - 2024/12/27

ER  -